Lupin Q4 FY26 Net Profit Jumps 89% YoY

Lupin reported Q4 FY26 net sales of ₹73,919 crore, up 32.9% YoY, with net income surging 89% to ₹14,604 crore.
EBITDA margin expanded to 29.4% driven by strong US sales growth and operational efficiencies, excluding forex and other income.
Key developments include US launch of Dapagliflozin, acquisition of VISUfarma, and European biosimilar approval for Ranibizumab.
The company outlined a strategic focus on complex generics, biosimilars, and expanding its India market share to 8th position.